Logo image of SXTC

CHINA SXT PHARMACEUTICALS IN (SXTC) Stock Fundamental Analysis

NASDAQ:SXTC - Nasdaq - VGG2161P1577 - Common Stock - Currency: USD

1.6465  -0.04 (-2.57%)

After market: 1.6 -0.05 (-2.82%)

Fundamental Rating

3

Overall SXTC gets a fundamental rating of 3 out of 10. We evaluated SXTC against 194 industry peers in the Pharmaceuticals industry. SXTC has an average financial health and profitability rating. SXTC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

5

1. Profitability

1.1 Basic Checks

In the past year SXTC was profitable.
In the past year SXTC has reported a negative cash flow from operations.
In the past 5 years SXTC always reported negative net income.
In multiple years SXTC reported negative operating cash flow during the last 5 years.
SXTC Yearly Net Income VS EBIT VS OCF VS FCFSXTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M -6M -8M -10M

1.2 Ratios

Looking at the Return On Assets, with a value of 18.70%, SXTC belongs to the top of the industry, outperforming 98.45% of the companies in the same industry.
The Return On Equity of SXTC (38.54%) is better than 97.42% of its industry peers.
With an excellent Return On Invested Capital value of 30.29%, SXTC belongs to the best of the industry, outperforming 98.45% of the companies in the same industry.
Industry RankSector Rank
ROA 18.7%
ROE 38.54%
ROIC 30.29%
ROA(3y)-16.86%
ROA(5y)-21.19%
ROE(3y)-32.52%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
SXTC Yearly ROA, ROE, ROICSXTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

The Profit Margin of SXTC (318.69%) is better than 99.48% of its industry peers.
With an excellent Operating Margin value of 340.71%, SXTC belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
SXTC has a Gross Margin (22.02%) which is in line with its industry peers.
In the last couple of years the Gross Margin of SXTC has declined.
Industry RankSector Rank
OM 340.71%
PM (TTM) 318.69%
GM 22.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.51%
GM growth 5Y-15.27%
SXTC Yearly Profit, Operating, Gross MarginsSXTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), SXTC is creating value.
Compared to 1 year ago, SXTC has more shares outstanding
The number of shares outstanding for SXTC has been increased compared to 5 years ago.
The debt/assets ratio for SXTC has been reduced compared to a year ago.
SXTC Yearly Shares OutstandingSXTC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
SXTC Yearly Total Debt VS Total AssetsSXTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

SXTC has an Altman-Z score of 6.99. This indicates that SXTC is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of SXTC (6.99) is better than 83.51% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that SXTC is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.06, SXTC perfoms like the industry average, outperforming 52.58% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 6.99
ROIC/WACC3.55
WACC8.53%
SXTC Yearly LT Debt VS Equity VS FCFSXTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

SXTC has a Current Ratio of 1.40. This is a normal value and indicates that SXTC is financially healthy and should not expect problems in meeting its short term obligations.
SXTC's Current ratio of 1.40 is on the low side compared to the rest of the industry. SXTC is outperformed by 71.13% of its industry peers.
A Quick Ratio of 1.35 indicates that SXTC should not have too much problems paying its short term obligations.
SXTC has a Quick ratio of 1.35. This is in the lower half of the industry: SXTC underperforms 66.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.35
SXTC Yearly Current Assets VS Current LiabilitesSXTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

SXTC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 117.22%, which is quite impressive.
Looking at the last year, SXTC shows a small growth in Revenue. The Revenue has grown by 6.99% in the last year.
The Revenue for SXTC have been decreasing by -22.75% on average. This is quite bad
EPS 1Y (TTM)117.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.72%
Revenue 1Y (TTM)6.99%
Revenue growth 3Y-26.11%
Revenue growth 5Y-22.75%
Sales Q2Q%-11.72%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SXTC Yearly Revenue VS EstimatesSXTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 0.04 indicates a rather cheap valuation of SXTC.
100.00% of the companies in the same industry are more expensive than SXTC, based on the Price/Earnings ratio.
SXTC's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.54.
Industry RankSector Rank
PE 0.04
Fwd PE N/A
SXTC Price Earnings VS Forward Price EarningsSXTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

79.38% of the companies in the same industry are more expensive than SXTC, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 27.33
SXTC Per share dataSXTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

SXTC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CHINA SXT PHARMACEUTICALS IN

NASDAQ:SXTC (7/18/2025, 8:14:30 PM)

After market: 1.6 -0.05 (-2.82%)

1.6465

-0.04 (-2.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.03%
Inst Owner Change136.35%
Ins Owners0.11%
Ins Owner ChangeN/A
Market Cap191.04M
Analysts0
Price TargetN/A
Short Float %0.06%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.04
Fwd PE N/A
P/S 105.06
P/FCF N/A
P/OCF N/A
P/B 12.71
P/tB 12.72
EV/EBITDA 27.33
EPS(TTM)40.81
EY2478.59%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.02
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 18.7%
ROE 38.54%
ROCE 40.41%
ROIC 30.29%
ROICexc N/A
ROICexgc N/A
OM 340.71%
PM (TTM) 318.69%
GM 22.02%
FCFM N/A
ROA(3y)-16.86%
ROA(5y)-21.19%
ROE(3y)-32.52%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.51%
GM growth 5Y-15.27%
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA 0.15
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 164.77
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.35
Altman-Z 6.99
F-Score3
WACC8.53%
ROIC/WACC3.55
Cap/Depr(3y)16.75%
Cap/Depr(5y)40.04%
Cap/Sales(3y)2.08%
Cap/Sales(5y)3.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)117.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.72%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)6.99%
Revenue growth 3Y-26.11%
Revenue growth 5Y-22.75%
Sales Q2Q%-11.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y144.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-8942.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9119%
OCF growth 3YN/A
OCF growth 5YN/A